Loading...

MDGL MADRIGAL PHARMACEUTICALS INC Company Mergers 8-K Filing

MDRG

MDGL

MADRIGAL PHARMACEUTICALS INC

(MDGL)

2026 8-K

Financial Results Released

Patent Agreement Update

Management Change

Financial Results Announced

Financial Statements

Debt Restructuring

Financial Statements

Management Change

Financial Results

Earnings Update

Financial Results

Earnings Reports

Amendment to Stock Plan

Sales Agreement with TD Sec...

Earnings Reports

Exercise of Underwriters Op...

Underwriting Agreement for ...

FDA Approval of Rezdiffra f...

Appointment of CFO

Financial Results Announcement

Financial Results Announcement

Departure of Directors or C...

Inducement Plan Adoption

Appointment of CEO and Dire...

FDA Acceptance of New Drug ...

Financial Results Announcement

Departure and Appointment o...

Amendment and Annual Meeting

Amendment to Sales Agreement

Financial Results Announcement

Financial Results Announcement

Loan Agreement Amendment

Phase 3 Clinical Trial Results

External Links:

On January 29, 2026, Madrigal Pharmaceuticals and Roche updated their agreement, giving Madrigal exclusive control over patent adjustments for Rezdiffra, with royalties to Roche unchanged until certain extensions expire. This is a significant event for the company's control over key assets.

AI Assistant

MADRIGAL PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.